Ensysce Biosciences Publishes Peer-Reviewed Clinical Data Demonstrating Overdose Protection with MPAR Technology

Ensysce Biosciences announced the first peer-reviewed clinical publication demonstrating oral overdose protection with its MPAR technology. The Phase 1 data, published in the Journal of Opioid Management, validates the first-in-class overdose-limiting opioid technology of PF614-MPAR. The MPAR technology maintains therapeutic opioid exposure while limiting additional opioid release when excessive numbers of pills are consumed, preventing large increases in opioid delivery. The technology is protected by a growing intellectual property portfolio extending through 2042.